{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:10:58Z","timestamp":1789603858783,"version":"build-2803163510"},"reference-count":62,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Intrathecal (IT) chemotherapy is essential in treating hematological malignancies, but it can lead to ascending paraplegia, a condition that currently lacks clear management guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic review, analyzing 1219 studies and 116 patients, adhering to PRISMA guidelines for individual patient data. The study, registered under PROSPERO (CRD42022362121), focused on the onset, diagnostic approaches, and therapeutic interventions associated with this complication, and management strategies to tackle the ascending paraplegia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Paraplegia typically manifests approximately 10 days after chemotherapy, irrespective of injection frequency. In 95% of cases, paralysis stabilizes around the umbilical region, although some patients progress to upper limb involvement and respiratory compromise. Despite various diagnostic methods, consistent inflammatory markers in blood or cerebrospinal fluid are lacking, with approximately 60% of patients showing normal magnetic resonance imaging results at presentation. Misdiagnoses often include transverse myelitis, Guillain-Barr\u00e9 syndrome, and autoimmune radiculitis. Common treatments such as corticosteroids and intravenous immunoglobulins show limited effectiveness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our review delineates the clinical entity of ascending paraplegia following IT chemotherapy, aiming to increase clinician awareness and provide prognostic insight. We introduce the term post-IT paraplegia syndrome to facilitate accurate diagnosis and optimize treatment strategies for affected patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdae217","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T17:03:41Z","timestamp":1734714221000},"source":"Crossref","is-referenced-by-count":3,"title":["Post-intrathecal chemotherapy-related paraplegia syndrome in hematological cancer patients: A systematic review"],"prefix":"10.1093","volume":"7","author":[{"given":"Matthijs","family":"Monnikhof","sequence":"first","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Hamming","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Princes Maxima Center , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Crnko","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Brandsma","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Princes Maxima Center , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"van Rhenen","sequence":"additional","affiliation":[{"name":"Center of Haemato-Oncology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Monnikhof","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Bovenschen","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]},{"name":"Department of Pathology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan","family":"Kaspers","sequence":"additional","affiliation":[{"name":"Pediatric Oncology, Emma Children\u2019s Hospital, University Medical Center , Amsterdam ,","place":["The Netherlands"]},{"name":"Pediatric Oncology, Princes Maxima Center , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs W H","family":"Flinsenberg","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]},{"name":"Center of Haemato-Oncology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"issue":"2","key":"2025010911323710600_CIT0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"issue":"4","key":"2025010911323710600_CIT0002","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","journal-title":"Genes Dis"},{"issue":"4","key":"2025010911323710600_CIT0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1043454219849576","article-title":"Symptoms in children receiving treatment for cancer-part I: fatigue, sleep disturbance, and nausea\/vomiting","volume":"36","author":"Hooke","year":"2019","journal-title":"J Pediatr Oncol Nurs."},{"issue":"1","key":"2025010911323710600_CIT0004","doi-asserted-by":"crossref","first-page":"1179555718809071","DOI":"10.1177\/1179555718809071","article-title":"Intrathecal methotrexate-induced necrotizing myelopathy: a case report and review of histologic features","volume":"11","author":"Tariq","year":"2018","journal-title":"Clin Med Insights Pathol"},{"issue":"3","key":"2025010911323710600_CIT0005","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10072-020-04647-4","article-title":"Intrathecal cytosine arabinoside-induced progression of chronic methotrexate myelopathy","volume":"42","author":"Mikhelashvili","year":"2021","journal-title":"Neurol Sci."},{"issue":"2","key":"2025010911323710600_CIT0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/milmed\/167.2.157","article-title":"Magnetic resonance imaging findings in a case of cytarabine-induced myelopathy","volume":"167","author":"Sherman","year":"2002","journal-title":"Mil Med."},{"issue":"3","key":"2025010911323710600_CIT0007","doi-asserted-by":"crossref","first-page":"103296","DOI":"10.1016\/j.retram.2021.103296","article-title":"Intrathecal methotrexate induced myelopathy, rare yet serious complication: a case report and review of the literature","volume":"69","author":"Bidikian","year":"2021","journal-title":"Curr Res Transl Med"},{"issue":"3","key":"2025010911323710600_CIT0008","doi-asserted-by":"crossref","first-page":"432","DOI":"10.4103\/1119-3077.151806","article-title":"Progressive myelopathy, a consequence of intra-thecal chemotherapy: case report and review of the literature","volume":"18","author":"Chukwu","year":"2015","journal-title":"Niger J Clin Pract."},{"issue":"2","key":"2025010911323710600_CIT0009","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/practneurol-2021-003154","article-title":"Myelopathy associated with intrathecal methotrexate","volume":"22","author":"Rodrigues","year":"2022","journal-title":"Pract Neurol."},{"issue":"11","key":"2025010911323710600_CIT0010","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/kjm2.12427","article-title":"Ascending myelopathy after intrathecal methotrexate","volume":"37","author":"Chiu","year":"2021","journal-title":"Kaohsiung J Med Sci."},{"issue":"3","key":"2025010911323710600_CIT0011","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/0971-5851.190361","article-title":"Subacute quadriplegic myelopathy following intrathecal methotrexate","volume":"37","author":"Maramattom","year":"2016","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"2","key":"2025010911323710600_CIT0012","first-page":"e46","article-title":"Transverse myelopathy following intrathecal administration of chemotherapy","volume":"48","author":"Teh","year":"2007","journal-title":"Singapore Med J."},{"issue":"1","key":"2025010911323710600_CIT0013","doi-asserted-by":"crossref","first-page":"e15334","DOI":"10.1111\/ped.15334","article-title":"Dorsal myelopathy after nelarabine and intrathecal methotrexate therapy","volume":"64","author":"Sawamura","year":"2022","journal-title":"Pediatr Int."},{"issue":"1","key":"2025010911323710600_CIT0014","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13256-015-0597-5","article-title":"Methotrexate myelopathy after intrathecal chemotherapy: a case report","volume":"9","author":"Murata","year":"2015","journal-title":"J Med Case Rep."},{"issue":"2","key":"2025010911323710600_CIT0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.24611","article-title":"Dorsal column myelopathy after intrathecal chemotherapy for leukemia","volume":"92","author":"Pinnix","year":"2017","journal-title":"Am J Hematol."},{"issue":"2","key":"2025010911323710600_CIT0016","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/0883073814527157","article-title":"Progressive myelopathy mimicking subacute combined degeneration after intrathecal chemotherapy","volume":"30","author":"Yi","year":"2015","journal-title":"J Child Neurol."},{"issue":"2","key":"2025010911323710600_CIT0017","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11060-015-1727-z","article-title":"Myelopathy following intrathecal chemotherapy in adults: a single institution experience","volume":"122","author":"Cachia","year":"2015","journal-title":"J Neurooncol."},{"issue":"1","key":"2025010911323710600_CIT0018","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1179\/2045772312Y.0000000081","article-title":"Dorsal column myelopathy following intrathecal chemotherapy for acute lymphoblastic leukemia","volume":"37","author":"Joseph","year":"2014","journal-title":"J Spinal Cord Med."},{"issue":"6","key":"2025010911323710600_CIT0019","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/neup.12135","article-title":"Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy case","volume":"34","author":"Shintaku","year":"2014","journal-title":"Neuropathology"},{"issue":"7","key":"2025010911323710600_CIT0020","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jocn.2012.06.018","article-title":"Methotrexate-induced myelopathy mimicking subacute combined degeneration of the spinal cord","volume":"20","author":"Gosavi","year":"2013","journal-title":"J Clin Neurosci."},{"issue":"1","key":"2025010911323710600_CIT0021","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1078155220929747","article-title":"Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: case report","volume":"27","author":"Amer-Salas","year":"2021","journal-title":"J Oncol Pharm Pract."},{"issue":"3","key":"2025010911323710600_CIT0022","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF00707111","article-title":"Necrotizing myelopathy associated with acute lymphoblastic leukemia. Case report and review of literature","volume":"49","author":"Grisold","year":"1980","journal-title":"Acta Neuropathol."},{"issue":"12","key":"2025010911323710600_CIT0023","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1002\/1097-0142(19940615)73:12<3037::AID-CNCR2820731223>3.0.CO;2-6","article-title":"Myelopathy after intrathecal chemotherapy. A case report with unique magnetic resonance imaging changes","volume":"73","author":"McLean","year":"1994","journal-title":"Cancer."},{"issue":"4","key":"2025010911323710600_CIT0024","doi-asserted-by":"crossref","first-page":"e234076","DOI":"10.1136\/bcr-2019-234076","article-title":"Case of neuromyelitis optica: bilateral sensorineural hearing loss and transverse myelopathy following intrathecal chemotherapy","volume":"13","author":"Castillo-Torres","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"6","key":"2025010911323710600_CIT0025","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/sj.sc.3101592","article-title":"Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin","volume":"42","author":"Jordan","year":"2004","journal-title":"Spinal Cord."},{"issue":"6","key":"2025010911323710600_CIT0026","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.leukres.2010.12.021","article-title":"The effect of cerebral spinal fluid replacement on acute myelopathy induced by intrathecal therapy of leukemia","volume":"35","author":"Wang","year":"2011","journal-title":"Leuk Res."},{"issue":"2","key":"2025010911323710600_CIT0027","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1552-6569.2007.00094.x","article-title":"MR findings of intrathecal chemotherapy-related myelopathy in two cases: mimicker of subacute combined degeneration","volume":"17","author":"Lu","year":"2007","journal-title":"J Neuroimaging."},{"issue":"2","key":"2025010911323710600_CIT0028","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000351848","article-title":"Lateral and dorsal column hyperintensity on magnetic resonance imaging in a patient with myelopathy associated with intrathecal chemotherapy","volume":"5","author":"Saito","year":"2013","journal-title":"Case Rep Neurol"},{"issue":"2","key":"2025010911323710600_CIT0029","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.currproblcancer.2016.11.005","article-title":"Nelarabine-associated reversible Guillain-Barr\u00e9-like syndrome or myelopathy in an adult patient with primary refractory T-lymphoblastic lymphoma","volume":"41","author":"Lalayanni","year":"2017","journal-title":"Curr Probl Cancer."},{"issue":"9","key":"2025010911323710600_CIT0030","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s10072-018-3435-x","article-title":"Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia","volume":"39","author":"Lapucci","year":"2018","journal-title":"Neurol Sci."},{"issue":"3","key":"2025010911323710600_CIT0031","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/1078155214562268","article-title":"Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: a case report and review of the literature","volume":"22","author":"Alsdorf","year":"2016","journal-title":"J Oncol Pharm Pract."},{"issue":"2","key":"2025010911323710600_CIT0032","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0887-8994(99)00040-5","article-title":"Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment","volume":"21","author":"Koh","year":"1999","journal-title":"Pediatr Neurol."},{"issue":"8","key":"2025010911323710600_CIT0033","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/j.1468-1331.2008.02201.x","article-title":"Pure motor lumbosacral radiculopathy after intrathecal chemotherapy","volume":"15","author":"Santos-Garc\u00eda","year":"2008","journal-title":"Eur J Neurol."},{"issue":"9","key":"2025010911323710600_CIT0034","first-page":"1887","article-title":"Neurotoxicity of intrathecal methotrexate: MR imaging findings","volume":"24","author":"Sandoval","year":"2003","journal-title":"AJNR Am J Neuroradiol."},{"issue":"17","key":"2025010911323710600_CIT0035","first-page":"1606","article-title":"Neurotoxicity of cancer chemotherapy","volume":"8","author":"Yang","year":"2013","journal-title":"Neural Regen Res"},{"issue":"2","key":"2025010911323710600_CIT0036","first-page":"65","article-title":"Myelitis Transvera: een zeldzame complicatie in de hemato-oncologie","author":"Hamming","year":"2022","journal-title":"Nederlands tijdschrift voor Hematologie"},{"issue":"1","key":"2025010911323710600_CIT0037","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"2025010911323710600_CIT0038","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"2","key":"2025010911323710600_CIT0039","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/sj.leu.2404495","article-title":"Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children","volume":"21","author":"Dufourg","year":"2007","journal-title":"Leukemia."},{"issue":"3","key":"2025010911323710600_CIT0040","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s11060-010-0435-y","article-title":"Neurologic complications after intrathecal liposomal cytarabine in combination with systemic polychemotherapy in primary CNS lymphoma","volume":"103","author":"Ostermann","year":"2011","journal-title":"J Neurooncol."},{"issue":"1","key":"2025010911323710600_CIT0041","first-page":"1","article-title":"Acute and long-term neurologic complications in children with acute lymphoblastic leukemia","volume":"48","author":"Ayta\u00e7","year":"2006","journal-title":"Turk J Pediatr."},{"issue":"4","key":"2025010911323710600_CIT0042","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/pbc.25850","article-title":"Rechallenging with intrathecal methotrexate after developing subacute neurotoxicity in children with hematologic malignancies","volume":"63","author":"Badke","year":"2016","journal-title":"Pediatr Blood Cancer."},{"issue":"4","key":"2025010911323710600_CIT0043","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MPH.0b013e318041f112","article-title":"Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis","volume":"29","author":"Benesch","year":"2007","journal-title":"J Pediatr Hematol Oncol."},{"issue":"1","key":"2025010911323710600_CIT0044","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11060-018-2849-x","article-title":"Efficacy of intrathecal chemotherapy in patients with central nervous system involvement of hematological malignancies: a retrospective analysis","volume":"139","author":"Dara","year":"2018","journal-title":"J Neurooncol."},{"issue":"2","key":"2025010911323710600_CIT0045","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3346\/jkms.2008.23.2.278","article-title":"Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia","volume":"23","author":"Han","year":"2008","journal-title":"J Korean Med Sci."},{"issue":"10","key":"2025010911323710600_CIT0046","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.clml.2019.05.014","article-title":"Refractory \u03b1\/\u03b2-hepatosplenic T-cell lymphoma with secondary CNS dissemination and severe morbidity related to intrathecal chemotherapy: a case report and literature review","volume":"19","author":"Lewis","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2025010911323710600_CIT0047","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.mph.0000168729.32463.7b","article-title":"Prospective evaluation of clinical and laboratory effects of intrathecal chemotherapy on children with acute leukemia","volume":"27","author":"Keidan","year":"2005","journal-title":"J Pediatr Hematol Oncol."},{"issue":"20","key":"2025010911323710600_CIT0048","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.2001.19.20.4014","article-title":"Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251","volume":"19","author":"Lee","year":"2001","journal-title":"J Clin Oncol."},{"issue":"7","key":"2025010911323710600_CIT0049","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.20143","article-title":"Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer."},{"issue":"1","key":"2025010911323710600_CIT0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000207697","article-title":"Intrathecal methotrexate causing paraplegia in a middle-aged woman","volume":"60","author":"Weiss","year":"1978","journal-title":"Acta Haematol."},{"issue":"4","key":"2025010911323710600_CIT0051","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/1078155214528018","article-title":"Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: case report and review of literature","volume":"21","author":"Ngo","year":"2015","journal-title":"J Oncol Pharm Pract."},{"issue":"1","key":"2025010911323710600_CIT0052","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.wneu.2019.05.123","article-title":"Spinal cord toxicity from intrathecal chemotherapy: a case with clinicopathologic correlation","volume":"128","author":"Dornbos","year":"2019","journal-title":"World Neurosurg"},{"issue":"6","key":"2025010911323710600_CIT0053","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/1097-0142(19860315)57:6<1083::AID-CNCR2820570602>3.0.CO;2-B","article-title":"Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A pediatric oncology group study","volume":"57","author":"Dunton","year":"1986","journal-title":"Cancer."},{"issue":"10","key":"2025010911323710600_CIT0054","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/1097-0142(19921115)70:10<2504::AID-CNCR2820701019>3.0.CO;2-H","article-title":"\u201cLocked-in syndrome\u201d after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma","volume":"70","author":"Kleinschmidt-DeMasters","year":"1992","journal-title":"Cancer."},{"issue":"8","key":"2025010911323710600_CIT0055","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/1097-0142(19811015)48:8<1724::AID-CNCR2820480807>3.0.CO;2-U","article-title":"Central and peripheral myelinopathy associated with systemic neoplasia and chemotherapy","volume":"48","author":"Mena","year":"1981","journal-title":"Cancer."},{"issue":"3","key":"2025010911323710600_CIT0056","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/mpo.2950190309","article-title":"Acute fatal myeloencephalopathy after combined intrathecal chemotherapy in a child with acute lymphoblastic leukemia","volume":"19","author":"von der Weid","year":"1991","journal-title":"Med Pediatr Oncol."},{"key":"2025010911323710600_CIT0057","volume-title":". An Update on Cancer Deaths in the United States: Atlanta","author":"Richardson","year":"2022"},{"issue":"6","key":"2025010911323710600_CIT0058","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.joad.2016.09.001","article-title":"Recent advances on acute paraplegia","volume":"5","author":"Vyshka","year":"2016","journal-title":"J Acute Dis"},{"issue":"12","key":"2025010911323710600_CIT0059","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00277-008-0546-0","article-title":"Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation","volume":"87","author":"Hilgendorf","year":"2008","journal-title":"Ann Hematol."},{"issue":"8","key":"2025010911323710600_CIT0060","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","article-title":"Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Blood."},{"issue":"6 Pt 1","key":"2025010911323710600_CIT0061","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0002-9343(89)90459-2","article-title":"Intrathecal cytosine arabinoside-induced acute, rapidly reversible paralysis","volume":"86","author":"Saleh","year":"1989","journal-title":"Am J Med."},{"issue":"1","key":"2025010911323710600_CIT0062","doi-asserted-by":"crossref","first-page":"111184","DOI":"10.1016\/j.jclinane.2023.111184","article-title":"Drainage or lavage as a salvage manoeuvre after intrathecal drug errors: a systematic review with therapeutic recommendations","volume":"89","author":"Koning","year":"2023","journal-title":"J Clin Anesth."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdae217\/61249106\/vdae217.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdae217\/61249106\/vdae217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/7\/1\/vdae217\/61249106\/vdae217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T11:33:07Z","timestamp":1736422387000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdae217\/7929778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdae217","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,12,20]]},"article-number":"vdae217"}}